Advertisement

International Journal of Hematology

, Volume 75, Issue 2, pp 154–160 | Cite as

Comparison of Pgp- and MRP-Mediated Multidrug Resistance in Leukemia Cell Lines

  • Yu-Ping Gong
  • Ting Liu
  • Yong-Qian Jia
  • Li Qin
  • Cheng-Qi Deng
  • Ren-Yang Ou Yang
Progress in Hematology

Abstract

Drug resistance is a major cause of the failure of anticancer chemotherapy. Multidrug resistance is often caused by over-expression of the P-glycoprotein (Pgp) or the multidrug resistance—related protein (MRP). In the present study, we compared daunorubicin (DNR) accumulation, subcellular distribution, and the effect of modulators on drug accumulation and subcel-lular distribution in the Pgp-expressing K562 cell line and the MRP-expressing HL60 cell line using reverse-transcriptase polymerase chain reaction, MTT (3-[4, 5-dimethylthiazol-z-yl]-2,5-diphenyltetrazolium bromide) drug cytotoxicity assay, fluo-rocytometry, and confocal laser scanning microscopy. The 2 resistant cell lines exhibit similar levels of resistance to DNR and decreased drug accumulation. Altered drug subcellular distribution in the resistant cell lines compared to that in the sensitive cell lines was shown and, moreover, differences in drug distributions between the 2 resistant cell lines were found. DNR fluorescence in the resistant HL60 cell line was distributed into punctate regions in the cytoplasm; the nucleus and other cytoplasm were almost negative. In contrast, the resistant K562 cells showed a bright fluorescent signal located in the peripheral cytoplasm and perinuclear region; the nucleus and other cytoplasmic regions showed no signal. Use of the modulator verapamil increased drug accumulation and restored the altered subcellular distribution of the drug in the 2 resistant cell lines. The Golgi apparatus inhibitor brefeldin A had similar action in the resistant HL60 line but had little effect in the resistant K562 line. Therefore, our study suggested that there were differences between the 2 resistant cell lines in the compartments sequestering DNR.

Key words

Multidrug resistance P-glycoprotein Multidrug resistance—related protein Drug accumulation and subcellular distribution 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Referencess

  1. 1.
    Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance.Annu Rev Biochem. 1989;58:137–171.CrossRefPubMedGoogle Scholar
  2. 2.
    Broxterman HJ, Pinedo HM. Energy metabolism in multidrug resistant tumor cells: a review.J Cell Pharmacol. 1991;2:239–247.Google Scholar
  3. 3.
    Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter.Annu Rev Biochem. 1993;62:385–427.CrossRefPubMedGoogle Scholar
  4. 4.
    Mcgrath T, Center MS. Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug.Cancer Res. 1988;48:3959–3963.PubMedGoogle Scholar
  5. 5.
    Coley HM, Workman P, Twentyman PR. Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression.Br J Cancer. 1991;63:351–357.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kuiper CM, Broxterman HJ, Baas F, et al. Drug transport variants without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin.J Cell Pharmacol. 1990;1:35–41.Google Scholar
  7. 7.
    Versantvoort CH, Broxterman HJ, Pinedo HM, et al. Energy-dependent processes involved in reduced drug accumulation in multidrug resistant human lung cancer cell lines without Pglycoprotein expression.Cancer Res. 1992;52:17–23.PubMedGoogle Scholar
  8. 8.
    Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line.Science. 1992;258:1650–1654.CrossRefPubMedGoogle Scholar
  9. 9.
    Krishnamachary N, Ma L, Zheng L, Safa AR, Center MS. Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin.Oncol Res. 1994;6:119–127.PubMedGoogle Scholar
  10. 10.
    Barrand MA, Heppel-Parton AC, Wright KA, Rabbitts PH, Twen-tyman PR. A 190k protein overexpressed in non-p-glycoprotein containing multidrug-resistant cells and its relationship to the MRP gene.J Natl Cancer Inst. 1994;86:110–117.CrossRefPubMedGoogle Scholar
  11. 11.
    Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Col S P, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs.Cancer Res. 1994;54:357–361.PubMedGoogle Scholar
  12. 12.
    Barrand MA, Rhodes T, Center MS, Twentyman PR. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein.Eur J Cancer. 1993;29A:408–415.CrossRefPubMedGoogle Scholar
  13. 13.
    Coley HM, Amos WB, Twentyman PR, Workman P. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines.Br J Cancer. 1993;67:1316–1323.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Breuninger LM, Paul S, Gaughan K, et al. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution.Cancer Res. 1995;55:5342–5347.PubMedGoogle Scholar
  15. 15.
    Sognier MA, Zhang Y, Eberle RL, Sweet RM, Altenberg GA, Belli JA. Sequestration of doxorubicin in vesicles in a multidrugresistant cell line (LZ-100).Biochem Pharmacol. 1994;48:391–401.CrossRefGoogle Scholar
  16. 16.
    Seidel A, Hasmann M, Loser R, et al. Intracellular localization vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-275 cells.Virchows Archiv. 1995;426:249–256.CrossRefGoogle Scholar
  17. 17.
    Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome.Blood. 1975;45:321–334.Google Scholar
  18. 18.
    Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.J Immunol Methods. 1983;65:55–63.CrossRefGoogle Scholar
  19. 19.
    Willingham MC, Richert ND, Cornwell MM, et al. Immunocyto-chemical localization of P170 at the plasma membrane of multidrug-resistant human cells.J Histochem Cytochem. 1987;35:1451–1456.CrossRefGoogle Scholar
  20. 20.
    Calcabrini A, Meschini S, Stringaro A, Cianfriglia M, Arancia G, Molinari A. Detection of P-glycoprotein in the nuclear envelope of multidrug resistant cells.Histochem J. 2000;32:599–606.CrossRefPubMedGoogle Scholar
  21. 21.
    Gervasoni JE Jr, Fields SZ, Krishna S, et al. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug cell lines using laser-assisted confocal microscopy.Cancer Res. 1991;51:4955–4963.PubMedGoogle Scholar
  22. 22.
    Shoji Y, Fisher MH, Periasamy A, Herman B, Juliano RL. Verapamil and cyclosporin A modulate doxorubicin toxicity by distinct mechanisms.Cancer Lett. 1991;57:209–218.CrossRefPubMedGoogle Scholar
  23. 23.
    Klausner RD, Donaldson JG, Lippincott-Schwartz J. Brefeldin A: insights into the control of membrane traffic and organelle structure.J Cell Biol. 1992;116:1071–1080.CrossRefPubMedGoogle Scholar
  24. 24.
    Gong YP, Wang YT, Chen FY, et al. Identification of the subcellular localization of daunorubicin in multidrug-resistant K562 cell line.Leukemia Res. 2000;24:769–774.CrossRefGoogle Scholar
  25. 25.
    Tartakoff AM, Vassalli P. Lectin-binding sites as markers of Golgi subcompartments: proximal-to-distal maturation of oligosaccharides.J Cell Biol. 1983;97:1243–1248.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  • Yu-Ping Gong
    • 1
  • Ting Liu
    • 1
  • Yong-Qian Jia
    • 1
  • Li Qin
    • 1
  • Cheng-Qi Deng
    • 1
  • Ren-Yang Ou Yang
    • 2
  1. 1.Department of Hematology, the First Affiliated HospitalWest China University of Medical ScienceSichuan
  2. 2.Leukemia Unit, Renji HospitalShanghai Second Medical UniversityShanghaiPeople’s Republic of China

Personalised recommendations